OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial
Phase of Trial: Phase II
Latest Information Update: 13 Jan 2017
At a glance
- Drugs Oxcarbazepine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PROXIMUS
- 07 Jun 2017 Biomarkers information updated
- 09 Jan 2017 Planned number of patients changed from 60 to 30.
- 09 Jan 2017 Planned End Date changed from 1 Jan 2018 to 1 Mar 2018.